BioWorld

Nov. 10, 2008

View Archived Issues

Onyx Will Develop Cancer Drug in $320M BTG Deal

Onyx Pharmaceuticals Inc. took another step toward building its pipeline by licensing an anticancer compound from London-based BTG plc, in a deal that could bring in as much as $320 million for the UK company. (BioWorld Today) Read More

Tarceva Hits Endpoint in Phase III Maintenance Therapy NSCLC Trial

Read More

NewCo News: Stealth Blockmir Blocks miRNA One Target mRNA at a Time

Read More

Dingell, Waxman Fight for House Energy and Commerce Panel

Read More

Other News To Note

Read More